RxDoctor Payments Data

Jack Cochran, MD

Internal Medicine · Corona, CANPI 1700974938

Payments from drug & device makers

$1,085in general payments, 2019–2025

Across 35 payments — averaging $30.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$240
  • AbbVie$237
  • Abbott$222
  • Novo Nordisk$161
  • Johnson & Johnson$85
  • Eisai Inc.$63
  • plus $77 from 4 others

What the payments were for

  • Food & beverage$1,085100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,085 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$35,131
Medicare patients
92
Services billed
261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban15$11,956
XareltoRivaroxaban11$10,479
Atorvastatin Calcium180$2,223
Albuterol Sulfate HfaAlbuterol Sulfate57$1,661
Acetaminophen-CodeineAcetaminophen With Codeine55$1,372
Ibuprofen92$1,353
Amlodipine Besylate177$1,044
Levothyroxine Sodium74$944
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen60$784
Tamsulosin Hcl28$729
Lisinopril87$692
Gabapentin65$688
Losartan Potassium62$642
Omeprazole35$630
Atenolol62$622

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$23$11,95615 claims
Johnson & JohnsonXarelto$85$10,47911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →